Abstract
Psoriasis is an autoimmune and inflammatory disease, which is estimated to affect 2–3% of the population in the world. PSORI-CM02 is an empirical formula of Chinese medicine optimized from Yin Xie Ling, which is widely used to treat psoriasis in China for decades. However, its antipsoriatic mechanisms are still not well understood. Here, we explored the therapeutic effects of PSORI-CM02 on psoriasis and its mechanisms of action in imiquimod-induced psoriasis-like mouse models and human HaCaT cells. In experiments in vitro, PSORI-CM02 significantly inhibited HaCaT cell proliferation in dose-dependent and time-dependent manners. Furthermore, it hindered the progression of HaCaT cell cycle and arrested HaCaT cells at G1 phase. On the other hand, our in vivo studies demonstrated that PSORI-CM02 dramatically reduced psoriasis area and severity index scores and lesion temperature in imiquimod-induced psoriatic mice. The antioxidative activities of glutathione, catalase, and superoxide dismutase were increased while oxidative activity of malonaldehyde was markedly decreased after treatments with PSORI-CM02. PSORI-CM02 also suppressed the mRNA expression of proinflammatory cytokines, including TNF-α, IL-6, and IL-17, and lowered their protein levels in the serum as well. In addition, PSORI-CM02 could reduce the expression of IKKα and NF-κB in psoriatic skin tissue. It also upregulated the proportion of CD4+ Foxp3+ regulatory T cells (Tregs) in both lymph nodes and spleens and promoted CD4+ CD25+ Treg proliferation in vitro. Taken together, our research demonstrated that PSORI-CM02 inhibited HaCaT cell proliferation by arresting them at G1 phase and alleviated systemic inflammation and psoriasis in mice via altering the oxidative/anti-oxidative status, tipping the balance between Th17 responsiveness and CD4+ Foxp3+ Treg generation, and suppressing the expression of proinflammatory cytokines as well as NF-κB signaling.
Highlights
Psoriasis is an autoimmune and inflammatory dermatologic disease, which affects about 2–3% of population in the world
We found that PSORI-CM02 suppressed HaCaT cell proliferation by hindering their cell cycle progression at G1 phase, inhibited the expression of proinflammatory cytokines and NF-κB signaling, upregulated CD4+ Foxp3+ regulatory T cells (Tregs) in vivo and promoted their in vitro expansion as well while reducing IL-17 production and ameliorating murine psoriasis
Psoriasis is known as a chronic inflammatory dermatologic disease that affects around 2–3% of the general population [11]
Summary
Psoriasis is an autoimmune and inflammatory dermatologic disease, which affects about 2–3% of population in the world. Nowadays, accumulating evidence suggests that patients with moderate or severe psoriasis may increase the risk of other diseases, including obesity, cancer, diabetes mellitus and the metabolic syndrome [3]. Our previous researches have shown that Chinese herbal medicine can provide an effective therapy for psoriasis [7,8,9,10]. PSORI-CM02, which was optimized based on Chinese herbal formula Yin-Xie Ling discovered by well-known professor Guo-Wei Xuan, is a novel formula of Chinese medicine that has been used to effectively treat psoriasis during recent years. PSORI-CM02 formula is further undergoing a randomized, double-blinded and placebo-controlled clinical trial for treating stable psoriasis vulgaris with a syndrome pattern of blood stasis in our hospital
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
